NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APTX shares have increased by 62.6% and is now trading at $3.95.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aptinyx.

Aptinyx will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Aptinyx Inc (NASDAQ:APTX) announced its earnings results on Thursday, May, 14th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The business had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative net margin of 1,540.42% and a negative return on equity of 47.99%.
View Aptinyx's earnings history.

6 brokerages have issued 1 year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $15.00. On average, they anticipate Aptinyx's share price to reach $9.67 in the next twelve months. This suggests a possible upside of 144.7% from the stock's current price.
View analysts' price targets for Aptinyx.

Media coverage about APTX stock has trended very positive on Saturday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Aptinyx.

Aptinyx saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 912,900 shares, a drop of 10.5% from the July 15th total of 1,020,000 shares. Based on an average daily trading volume, of 421,500 shares, the days-to-cover ratio is presently 2.2 days. Approximately 4.1% of the shares of the stock are short sold.
View Aptinyx's Current Options Chain.

Some companies that are related to Aptinyx include Legend Biotech (AMTI), ImmunoGen (IMGN), Passage Bio (KROS), ZIOPHARM Oncology (ZIOP), Tricida (TCDA), Akouos (AKUS), Frequency Therapeutics (FREQ), Eagle Pharmaceuticals (EGRX), Flexion Therapeutics (FLXN), Vanda Pharmaceuticals (VNDA), Trillium Therapeutics (TRIL), G1 Therapeutics (GTHX), Aprea Therapeutics (APRE), Stemline Therapeutics (STML) and Collegium Pharmaceutical (COLL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.45%), Meridian Wealth Management LLC (0.07%), New York State Common Retirement Fund (0.05%), Leap Investments LP (0.03%) and UBS Group AG (0.02%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen.
View institutional ownership trends for Aptinyx.

APTX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meridian Wealth Management LLC, New York State Common Retirement Fund, Leap Investments LP, and UBS Group AG. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen.
View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.95.

Aptinyx has a market capitalization of $180.36 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]